CymaBay Therapeutics

NEWS
Seladelpar, which Gilead acquired when it bought CymaBay in February for $4.3 billion, showed positive results for reducing pruritus in primary biliary cholangitis patients and reducing inflammation.
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
Mergers and acquisitions are trending upward as Novo Nordisk, Gilead, and Johnson & Johnson kick off the year with big deals. AI and other scientific advances will likely be the focus of M&As yet to come.
Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
Analysts said CymaBay’s seladelpar is emerging as the “therapy of choice in the second-line setting” and “could impact the treatment landscape” across a spectrum of primary biliary cholangitis patients.
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
With Monkeypox, COVID-19, Long COVID symptoms and persistent diseases like cancer and Alzheimer’s, the world is dealing with a lot right now. Here’s a look at the latest in clinical trial news.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.
IN THE PRESS
CymaBay Therapeutics, Inc. announced that the Marketing Authorization Application for seladelpar, for the treatment of primary biliary cholangitis including pruritus in adults without cirrhosis or with compensated cirrhosis who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency.
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC).
CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024 in connection with the employees’ commencement of employment at CymaBay.
CymaBay Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid.
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.
CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of inducement awards to two employees on January 12, 2024 in connection with the employees’ commencement of employment at CymaBay.
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC).
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.